CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

KYNTRA BIO, INC.

KYNB
$21M
Micro Cap
NASDAQPharmaceutical PreparationsBiotechnology🇺🇸North AmericaSAN FRANCISCO52 employees

Kyntra Bio, Inc. (formerly FibroGen, Inc.) is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.

Website

Drugs in Pipeline

1

Phase 3 Programs

1

Upcoming Catalysts

0

Next Catalyst

None scheduled

Market Overview

Stock performance and key metrics

KYNB News
Catalyst Timeline

0 upcoming, 0 past

No catalysts found.

Drug Pipeline
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply